12:00 AM
 | 
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MA09-hRPE cells: Phase I/II ongoing

Advanced Cell said a DSMB recommended enrolling the final 2 patients in the second dose cohort of an open-label, dose-escalation, U.S. Phase I/II trial based on a review of safety...

Read the full 129 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >